ArticleFederal practitioner : for the health care professionals of the VA, DoD, and PHS2026
Investigating Real-World Tolerance and Dose Reductions of Oncology Multikinase Inhibitors in a VA Population.
Article in Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral multikinase inhibitors (MKIs) are widely used and effective targeted therapies for patients with cancer. These agents can have substantial drug-drug interactions and adverse effects (AEs), which can make them difficult to tolerate. This study sought to evaluate the real-world tolerance of MKIs prescribed by the hematology/oncology clinic at the Veterans Affairs North Texas Health Care System (VANTHCS) to guide clinicians in the selection of starting doses and in setting expectations for the management of dose titrations. Methods: A retrospective chart review of veterans managed by the VANTHCS hematology/oncology clinic with a prescription for axitinib, cabozantinib, lenvatinib, pazopanib, regorafenib, sorafenib, or sunitinib was conducted for patients treated from January 1, 2014, to October 31, 2024. The primary outcome was the evaluation of MKI tolerance through determining the relative dose intensity (RDI) and mean and median time on therapy. Secondary outcomes included rates of AEs and adjustments in doses. Results: One hundred seventy veterans with 208 MKI prescriptions met the study inclusion criteria. The overall combined mean MKI RDI was 67.5%. Individual mean RDIs were 71.0% for axitinib, 59.6% for cabozantinib, 63.7% for lenvatinib, 82.3% for pazopanib, 61.2% for regorafenib, 49.0% for sorafenib, and 85.5% for sunitinib. The mean and median time on therapy for all MKIs (excluding days of therapy that were held) was 155 and 95 days, respectively. There were 376 AEs. Eighty-one prescriptions (38.9%) started at the indicated dose and 127 prescriptions (61.1%) were initiated at a reduced dose because of baseline concerns. Across both groups, 90 prescriptions (43.3%) required further dose reduction during therapy. Conclusions: Oncology MKI therapies used at VANTHCS were difficult for veterans to tolerate and ultimately led to suboptimal dosing. Clinicians may use these data to guide decision-making when initiating and managing MKI agents in this population.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.